Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncologica
Durvalumab was associated with prolonged progression-free survival, while concomitant radiotherapy showed a trend towards improvement in locoregional and local control in patients aged ≥70. There was no significant difference in treatment toxicity found in the exploratory Mann-Whitney U analysis between the two age groups.
Authors
- Barbara Zellinger
- Raphaela Moosbrugger
- Josef Karner
- Martin Heilmann (ORCID: https://orcid.org/0009-0006-0759-5053)
- Falk Roeder (ORCID: https://orcid.org/0000-0003-3787-7386)
- Markus Stana (ORCID: https://orcid.org/0000-0002-0155-0384)
- Elvis Ruznic (ORCID: https://orcid.org/0000-0001-7686-1008)
- Brane Grambozov (ORCID: https://orcid.org/0000-0003-2454-7425)
- Danijela Minasch
- Franz Zehentmayr (ORCID: https://orcid.org/0000-0001-5931-3907)
- Marisa Klebermass
- Georg B. Gruber
- Ayurzana Purevdorj (ORCID: https://orcid.org/0009-0002-2071-381X)
Institutions
- Innsbruck Medical University (AT)
- Paracelsus Medical University (AT)
- Klinik Hietzing (AT)
- Comprehensive Cancer Center Vienna (AT)
- Otto Wagner Hospital (AT)
- AGO Austria (AT)
Publication Details
- Journal
- Medical Sciences
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3390/medsci13040305
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz